Epigenetic Regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA Methylation and Histone Modification

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Fu, Baisheng ^a   Wang, Hongwei ^b   Wang, Jinhua ^b   Barouhas, Ivana ^b   Liu, Wanqing ^c   Shuboy, Adam ^b   Bushinsky, David A ^d   Zhou, Dongsheng ^a   Favus, Murray J ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; HISTONE H3; TRICHOSTATIN A; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BONE MARROW CELL; BONE MORPHOGENETIC PROTEIN 2 GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE MODIFICATION; IN VITRO STUDY; MALE; NONHUMAN; PROMOTER REGION; PYROSEQUENCING; RAT; REPORTER GENE; STROMA CELL;

ANIMALS; AZACITIDINE; BONE MORPHOGENETIC PROTEIN 2; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HISTONES; HYPERCALCIURIA; MALE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; VITAMIN D;

RATTUS;

EID: 84876434818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061423     Document Type: Article

References (52)

1. Liberman UA, Sperling O, Atsmon A, Frank M, Modan M, et al. (1968) Metabolic and calcium kinetic studies in idiopathic hypercalciuria. J Clin Invest 47: 2580-2590.
2. Bushinsky DA, Favus MJ, (1988) Mechanism of hypercalciuria in genetic hypercalciuric rats. Inherited defect in intestinal calcium transport. J Clin Invest 82: 1585-1591.
3. Tsuruoka S, Bushinsky DA, Schwartz GJ, (1997) Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 51: 1540-1547.
4. Bushinsky DA, (1996) Genetic hypercalciuric stone forming rats. Semin Nephrol 16: 448-457.
5. Grynpas M, Waldman S, Holmyard D, Bushinsky DA, (2009) Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength. J Bone Miner Res 24: 1420-1426.
6. Pietschmann F, Breslau NA, Pak CY, (1992) Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 7: 1383-1388.
7. Asplin JR, Donahue S, Kinder J, Coe FL, (2006) Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int 70: 1463-1467.
8. Yao J, Kathpalia P, Bushinsky DA, Favus MJ, (1998) Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest 101: 2223-2232.
9. Karnauskas AJ, van Leeuwen JP, van den Bemd GJ, Kathpalia PP, DeLuca HF, et al. (2005) Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Miner Res 20: 447-454.
10. Bai S, Favus MJ, (2006) Vitamin D and calcium receptors: links to hypercalciuria. Curr Opin Nephrol Hypertens 15: 381-385.
11. Bai S, Wang H, Shen J, Zhou R, Bushinsky DA, et al. (2010) Elevated vitamin D receptor levels in genetic hypercalciuric stone-forming rats are associated with downregulation of Snail. J Bone Miner Res 25: 830-840.
12. Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Ketagiri T, et al. (1996) Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem Biophys Res Commun 220: 366-371.
13. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, et al. (2001) Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2: 203-216.
14. Feldman D, Pike JW, Adams JS (2011) Vitamin D, third ed. London: Academic Press. 6 p.
15. Walters MR, (1992) Newly identified actions of the vitamin D endocrine system. Endocr Rev 13: 719-764.
16. Bouillon R, Okamura WH, Norman AW, (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257.
17. DeLuca HF, (1988) The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J 2: 224-236.
18. Erben RG, Scutt AM, Miao D, Kollenkirchen U, Haberey M, (1997) Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138: 4629-4635.
19. Erben RG, Bromm S, Stangassinger M, (1998) Therapeutic efficacy of 1alpha,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1alpha,25-dihydroxyvitamin D3 on bone. Endocrinology 139: 4319-4328.
20. van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA, (2001) Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 11: 199-226.
21. Tanaka H, Seino Y, (2004) Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem Mol Biol 89-90: 343-345.
22. Sooy K, Sabbagh Y, Demay MB, (2005) Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J Cell Biochem 94: 81-87.
23. Ecarot B, Desbarats M, (1999) 1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 140: 1192-1199.
24. Hines ER, Kolek OI, Jones MD, Serey SH, Sirjani NB, et al. (2004) 1,25-dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem 279: 46406-46414.
25. Drissi H, Pouliot A, Koolloos C, Stein JL, Lian JB, et al. (2002) 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274: 323-333.
26. Yamaguchi M, Weitzmann MN, (2012) High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro. Int J Mol Med 29: 934-938.
27. Celeste AJ, Iannazi JA, Taylor RC, Hewick RM, Rosen V, et al. (1990) Identification of transforming growth factor β family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87: 9843-9847.
28. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, et al. (1988) Novel regulators of bone formation: Molecular clones and activities. Science 242: 1528-1534.
29. Harris SE, Bonewald LF, Harris MA, Sabatini M, Dallas S, et al. (1994) Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res 9: 855-863.
30. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, et al. (1990) Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 87: 2220-2224.
31. Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Ketagiri T, et al. (1996) Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem Biophys Res Commun 220: 366-371.
32. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, et al. (2002) Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 17: 101-110.
33. Cho TJ, Gerstenfeld LC, Einhorn TA, (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17: 513-520.
34. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, et al. (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38: 1424-1429.
35. Gnecchi M, Melo LG, (2009) Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 482: 281-294.
36. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
37. Wang HW, Breslin MB, Lan MS, (2007) Pdx-1 modulates histone H4 acetylation and insulin gene expression in terminally differentiated alpha-TC-1 cells. Pancreas 34: 248-253.
38. Giannini S, Nobile M, Sartori L, Calo L, Tasca A, et al. (1998) Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol 50: 94-100.
39. Tasca A, Cacciola A, Ferrarese P, Ioverno E, Visona E, et al. (2002) Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology 59: 865-869; discussion 869.
40. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325-349.
41. Norman AW, (2006) Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147: 5542-5548.
42. MacDonald PN, Baudino TA, Tokumaru H, Dowd DR, Zhang C, (2001) Vitamin D receptor and nuclear receptor coactivators: Crucial interactions in vitamin D-mediated transcription. Steroids 66: 171-176.
43. Abrams KL, Xu J, Nativelle-Serpentini C, Dabirshahsahebi S, Rogers MB, (2004) An evolutionary and molecular analysis of Bmp2 expression. J Biol Chem 279: 15916-15928.
44. Jiang S, Chandler RL, Fritz DT, Mortlock DP, Rogers MB, (2010) Repressive BMP2 gene regulatory elements near the BMP2 promoter. Biochem Biophys Res Commun 392: 124-128.
45. Saxonov S, Berg P, Brutlag DL, (2006) A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103: 1412-1417.
46. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, et al. (2007) Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3: 2023-2036.
47. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
48. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, et al. (2008) Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30: 755-766.
49. Krishnan S, Horowitz S, Trievel RC, (2011) Structure and function of histone H3 lysine 9 methyltransferases and demethylases. Chembiochem 12: 254-263.
50. Jackson JP, Johnson L, Jasencakova Z, Zhang X, PerezBurgos L, et al. (2004) Dimethylation of histone H3 lysine 9 is a critical mark for DNA methylation and gene silencing in Arabidopsis thaliana. Chromosoma 112: 308-315.
51. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D, (2001) Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11: 162-166.
52. Eberharter A, Becker PB, (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3: 224-229.